Angela Kim
she/her/hers
About
Research
Publications
2026
NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition
Kim A, Bhardwaj P, Rehman S, Zhao S, Lucas K, Noronha K, Bhatt D, Friedman S, Morotti R, Sundaram R, Dela Cruz F, Feinberg T, Ramakrishnan S, Xue W, Barkauskas D, Hall D, Shern J, Sun W, Barr F, Yi J, Spurrier J, Yu A, Brenner C, Heer C, Heske C, Vasquez J. NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition. Molecular Cancer Therapeutics 2026, 10.1158/1535-7163.mct-25-0619. PMID: 42017774, PMCID: PMC13184901, DOI: 10.1158/1535-7163.mct-25-0619.Peer-Reviewed Original Researchpatient-derived xenograftsNAMPT inhibitorstherapeutic windowlack of predictive biomarkersbiomarker-driven strategiesprotein expressiontumor cell stainingChildren's Oncology GroupRMS cell linesorthotopic PDX modelsin vivo efficacypreclinical promisetumor regressionprimary tumorOncology GroupPDX modelspredictive biomarkerspediatric rhabdomyosarcomarhabdomyosarcoma modelmetabolic vulnerabilitiespromoter hypermethylationpromoter methylationrhabdomyosarcomaclinical trialsNA administration
2024
ASAP1 and ARF1 Regulate Myogenic Differentiation in Rhabdomyosarcoma by Modulating TAZ Activity
Hebron K, Perkins O, Kim A, Jian X, Girald-Berlingeri S, Lei H, Shern J, Conner E, Randazzo P, Yohe M. ASAP1 and ARF1 Regulate Myogenic Differentiation in Rhabdomyosarcoma by Modulating TAZ Activity. Molecular Cancer Research 2024, 23: 95-106. PMID: 39495123, PMCID: PMC11799837, DOI: 10.1158/1541-7786.mcr-24-0490.Peer-Reviewed Original ResearchConceptsADP-ribosylation factorGTPase-activating proteinMEK1/2 inhibitiontranscription regulator 1tumor suppressor functionfusion-negative RMSGTPase Arf1differentiation therapyGAP activityGTPase activitytranscriptional regulationARF1TAZ activityHippo pathwaymyogenic differentiationtranscription factor expressionASAP1differentiation-inducing therapypathway componentsmolecular mechanismsregulator 1
2023
Usability and Satisfaction Testing of Game-Based Learning Avatar-Navigated Mobile (GLAm), an App for Cervical Cancer Screening: Mixed Methods Study
Wanberg L, Kim A, Vogel R, Sadak K, Teoh D. Usability and Satisfaction Testing of Game-Based Learning Avatar-Navigated Mobile (GLAm), an App for Cervical Cancer Screening: Mixed Methods Study. JMIR Formative Research 2023, 7: e45541. PMID: 37552527, PMCID: PMC10445170, DOI: 10.2196/45541.Peer-Reviewed Original Researchcervical cancer screeningcancer screeningmixed methods studymethods studycervical cancer screening uptakestudy participantscancer screening knowledgecancer screening uptakeDirected content analysissurvey studyTechnology Acceptance Modelscreening processyoung adultsnegative perceptionsweb-based surveyscreening knowledgescreening uptake
2022
The combination of trametinib and ganitumab is effective in RAS-mutated PAX-fusion negative rhabdomyosarcoma models
Hebron K, Wan X, Roth J, Liewehr D, Sealover N, Frye W, Kim A, Stauffer S, Perkins O, Sun W, Isanogle K, Robinson C, James A, Awasthi P, Shankarappa P, Luo X, Lei H, Butcher D, Smith R, Edmondson E, Chen J, Kedei N, Peer C, Shern J, Figg W, Chen L, Hall M, Difilippantonio S, Barr F, Kortum R, Robey R, Vaseva A, Khan J, Yohe M. The combination of trametinib and ganitumab is effective in RAS-mutated PAX-fusion negative rhabdomyosarcoma models. Clinical Cancer Research 2022, 29: 472-487. PMID: 36322002, PMCID: PMC9852065, DOI: 10.1158/1078-0432.ccr-22-1646.Peer-Reviewed Original ResearchConceptsFN-RMScell linesIGF1R inhibitorsMEK inhibitionmurine modelMEK1/2 inhibitorRas/MAP kinase pathwayxenograft modelpatient-derived xenograft modelsphase I/II clinical trialsinhibition of tumor growthcombination of trametinibSCID-beige micepreclinical murine modelseffects of trametinibphosphorylation of AktRMS cell lineskinase pathwaytolerability profileBMS-754807molecular mechanismsEpithelial STAT6 O-GlcNAcylation drives a concerted anti-helminth alarmin response dependent on tuft cell hyperplasia and Gasdermin C
Zhao M, Ren K, Xiong X, Xin Y, Zou Y, Maynard J, Kim A, Battist A, Koneripalli N, Wang Y, Chen Q, Xin R, Yang C, Huang R, Yu J, Huang Z, Zhang Z, Wang H, Wang D, Xiao Y, Salgado O, Jarjour N, Hogquist K, Revelo X, Burlingame A, Gao X, von Moltke J, Lin Z, Ruan H. Epithelial STAT6 O-GlcNAcylation drives a concerted anti-helminth alarmin response dependent on tuft cell hyperplasia and Gasdermin C. Immunity 2022, 55: 623-638.e5. PMID: 35385697, PMCID: PMC9109499, DOI: 10.1016/j.immuni.2022.03.009.Peer-Reviewed Original ResearchConceptsO-GlcNAcylationunconventional secretionIL-25IL-33protein O-GlcNAcylationO-GlcNAc transferasetype 2 immune responseshelminth infectionssecretion of IL-33transcription factor STAT6anti-helminth immunityintestinal epithelial cellsIL-33 secretionO-GlcNAcfamily genesprotein modificationcytokine milieucell hyperplasiahuman diseases
News
News
- August 21, 2026
New Haven Students Participate in 2026 Yale Neuroscience Summer Scholars Program
- June 02, 2026
Ninth Annual YCC Trainee Research Colloquium Celebrates Outstanding Cancer Research
- May 01, 2025
New Research Presented from Yale Cancer Center at #AACR25
- April 21, 2025
Yale Cancer Center Research Breakthroughs Unveiled at AACR Annual Meeting
Get In Touch
Contacts
Email